Literature DB >> 4031121

Patterns of muscarinic cholinergic binding in the striatum and their relation to dopamine islands and striosomes.

M A Nastuk, A M Graybiel.   

Abstract

The distribution of muscarinic cholinergic binding sites in the striatum was studied in relation to the locations of other neurochemical markers in the developing rat, cat, ferret, and human. In addition, patterns of striatal muscarinic binding were studied in the adult cat. Receptor binding autoradiography was carried out with tritiated propylbenzilylcholine mustard [( 3H]-PrBCM), an irreversible muscarinic antagonist, and subsequent serial section analyses involved comparisons among patterns of muscarinic binding, catecholamine histofluorescence, acetylcholinesterase (AChE) staining, Nissl staining, and cell labeling with [3H]-thymidine. Muscarinic binding in the immature striatum was characterized by local patchiness as well as regional density gradients in all species, with the most complex patterns appearing in the human. Patches of dense muscarinic binding were shown to lie in register with fluorescent dopamine islands (rat, cat, ferret), with AChE-positive patches (all species), and with clusters of neurons pulse-labeled by exposure to [3H]-thymidine on embryonic day 27 (ferret). At the developmental stages examined, the [3H]-PrBCM-positive patches were roughly aligned with regions of weak Nissl staining (cat, human). Striatal [3H]-PrBCM binding in the adult cat was dense, and though it usually appeared nearly homogeneous, in some sections patches of elevated binding were present. These had as counterparts, in neighboring sections, AChE-poor striosomes. We conclude that during development muscarinic cholinergic function is compartmentalized in the striatum in association with dopamine-containing afferents, and that this compartmentalization may persist to some degree in the adult.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031121     DOI: 10.1002/cne.902370204

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  8 in total

Review 1.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 2.  Direct dopamine terminal regulation by local striatal microcircuitry.

Authors:  Suzanne O Nolan; Jennifer E Zachry; Amy R Johnson; Lillian J Brady; Cody A Siciliano; Erin S Calipari
Journal:  J Neurochem       Date:  2020-06-19       Impact factor: 5.372

3.  Ephrin-A binding and EphA receptor expression delineate the matrix compartment of the striatum.

Authors:  L S Janis; R M Cassidy; L F Kromer
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

4.  An afterhyperpolarization recorded in striatal cells 'in vitro': effect of dopamine administration.

Authors:  A Rutherford; M Garcia-Munoz; G W Arbuthnott
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

5.  Neurochemical characterization of the tree shrew dorsal striatum.

Authors:  Matthew W Rice; Rosalinda C Roberts; Miguel Melendez-Ferro; Emma Perez-Costas
Journal:  Front Neuroanat       Date:  2011-08-17       Impact factor: 3.856

6.  Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments.

Authors:  Jill R Crittenden; Ann M Graybiel
Journal:  Front Neuroanat       Date:  2011-09-07       Impact factor: 3.856

7.  The non-human primate striatum undergoes marked prolonged remodeling during postnatal development.

Authors:  Lee J Martin; Linda C Cork
Journal:  Front Cell Neurosci       Date:  2014-09-22       Impact factor: 5.505

8.  Involvement of HCN Channel in Muscarinic Inhibitory Action on Tonic Firing of Dorsolateral Striatal Cholinergic Interneurons.

Authors:  Zhe Zhao; Kang Zhang; Xiaoyan Liu; Haitao Yan; Xiaoyun Ma; Shuzhuo Zhang; Jianquan Zheng; Liyun Wang; Xiaoli Wei
Journal:  Front Cell Neurosci       Date:  2016-03-22       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.